Background and aim Intrahepatic cholangiocarcinoma (ICC) is an aggressive liver malignancy with limited prognostic tools to guide treatment strategies. This study aimed to develop and validate a preoperative prognostic model combining tumor burden score (TBS), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9), termed the TCCA model, to predict outcomes in patients with ICC undergoing hepatectomy. Methods Patients who underwent curative resection for ICC between 2014 and 2020 were retrospectively identified from a multi-institutional database. The impact of the TCCA model on overall survival (OS) and recurrence-free survival (RFS) was evaluated in training and validation cohorts. Predictive performance was evaluated using the area under the Receiver Operating Characteristic curve (AUC), the Akaike Information Criterion (AIC), and the C-index. Results A total of 849 patients were included. Lower TCCA scores were associated with better median OS (score 0: 59.7 months; score 1: 31.3 months; score 2: 19.4 months; score 3: 11.5 months, respectively) and median RFS (28.8; 15.4; 9.7; 8.1 months, respectively). The TCCA model performed well in both the training cohort (AUC: 0.697 for OS and 0.649 for RFS) and the validation cohort (AUC: 0.672 for OS and 0.632 for RFS), outperforming the 8th edition TNM system and other models, with the highest C-index (0.734) and lowest AIC (3840). Subgroup analyses demonstrated that the TCCA model maintained good discriminative ability among patients with negative CEA or CA19–9 levels. Conclusion The TCCA model accurately stratifies ICC patients for OS and RFS after resection. It provides a simple and practical tool for preoperative risk assessment, supporting individualized surgical decision-making and individualized patient counseling.
Fu et al. (Wed,) studied this question.